SCHEMBL4059846

SCHEMBL4059846

FC(F)(F)Oc1cccc(-c2nc3ccc(-c4ccccc4C(F)(F)F)cc3o2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 3/20 0.47
PIK3R1 P27986 1/20 0.44
PIK3CA P42336 1/20 0.44
VSIR Q9H7M9 2/20 0.43
BACE1 P56817 1/20 0.43
GRM5 P41594 1/20 0.43
S1PR1 P21453 3/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SCN9A Q15858 1/20 0.40
MAPT P10636 2/20 0.40
GPR119 Q8TDV5 2/20 0.40
TP53 P04637 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
S1PR3 Q99500 1/20 0.39
PTPN2 P17706 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051500 0.89 NPC1 (0.54) P2RY14PIK3R1PIK3CAVSIRBACE1
SCHEMBL4057847 0.88 VSIR (0.56) P2RY14VSIRGRM5S1PR1NPC1
SCHEMBL4058082 0.85 BACE1 (0.51) PIK3R1PIK3CAVSIRBACE1S1PR1
SCHEMBL4051587 0.84 VSIR (0.51) PIK3R1PIK3CAVSIRBACE1S1PR1
SCHEMBL4057762 0.84 BACE1 (0.46) P2RY14PIK3R1PIK3CAVSIRBACE1
SCHEMBL4053408 0.83 NPC1 (0.51) PIK3R1PIK3CAVSIRBACE1S1PR1
SCHEMBL4055495 0.82 NPC1 (0.58) P2RY14S1PR1NPC1LMNACASP3
SCHEMBL4053451 0.81 NPC1 (0.52) PIK3R1PIK3CABACE1NPC1LMNA
SCHEMBL4054585 0.80 GPR119 (0.50) PIK3R1PIK3CAVSIRBACE1S1PR1
SCHEMBL4054470 0.80 ADORA1 (0.47) P2RY14GRM5S1PR1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B P2RY14 3595/4885PIK3R1 565/4885PIK3CA 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.